Risk of relapse after meningococcal C conjugate vaccine in nephrotic syndrome

Lancet

Volumn 362, Issue 9382, 2003, Pages 449-450

  Abeyagunawardena, A S ^a   Goldblatt, D ^a   Andrews, N ^b   Trompeter, R S ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; MENINGOCOCCAL C CONJUGATE VACCINE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE; HUMAN; MALE; NEPHROTIC SYNDROME; NORMAL HUMAN; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; STATISTICAL SIGNIFICANCE; VACCINATION;

EID: 0042736671     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14072-X     Document Type: Article

References (4)

1. Trompeter R.S., Lloyd B.W., Hicks J., White R.H., Cameron J.S. Long-term outcome for children with minimal change nephrotic syndrome. Lancet. 1:1985;368-370.
2. Schnaper H.W. The immune system in minimal change nephrotic syndrome. Pediatr Nephrol. 3:1989;101-110.
3. Yap H., Cheung W., Murugasu M., Sim S., Seah C., Jordon S.C. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol. 10:1999;529-537.
4. Goldblatt D. Conjugate vaccines. Clin Exp Immunol. 119:2000;1-3.